EXOZ vs PATH
eXoZymes, Inc. (EXOZ) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
eXoZymes, Inc. (EXOZ) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported EXOZ revenue for 2023-12-31 was $70.1K. Net income was -$2.0M. Revenue was down 1.0% from 2023-09-30 to 2023-12-31. EXOZ currently screens at market cap $83.5M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
EXOZ currently screens at market cap $83.5M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the EXOZ and PATH stock pages for the full models.
Not investment advice.